Factors Influencing Completion of Therapy with High-Dose Interferon Alfa-2b for High-Risk Melanoma
Author Information
Author(s): Levesque N. RN, Mitchinson K. RN, Lawrie D. RN, Fedorak L. RN, MacDonald D. RN, Normand C. RN, Pouliot J.F. PhD
Primary Institution: Hamilton Regional Cancer Centre
Hypothesis
Close monitoring and frequent follow-ups would help nurses to identify factors that might be contributing to early discontinuation of interferon alfa-2b regimen by patients during the 52 weeks of therapy.
Conclusion
Only 41% of patients completed the 1-year treatment course, but higher fluid intake was associated with increased adherence to therapy.
Supporting Evidence
- 75 patients (33.3%) discontinued interferon during the induction phase.
- 58 patients (25.8%) discontinued during the maintenance phase.
- Patients with a daily fluid intake greater than 1.5 L were more likely to complete therapy.
Takeaway
This study looked at why some patients stop taking their medicine for melanoma. It found that drinking more water helps people stick to their treatment.
Methodology
A 1-year observational, multicentre, open-label study conducted in 23 tertiary-care centres across Canada.
Limitations
The study's completion rates were lower than those reported in controlled clinical trials.
Participant Demographics
64% of participants were men, with a mean age of 51.7 years.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website